Grants for Public Housing Authorities

This grant provides financial support for senior graduate students from diverse backgrounds to complete their dissertations in aging research, promoting a more inclusive scientific workforce.

This funding opportunity supports innovative clinical trials aimed at developing advanced imaging technologies to visualize the inner ear's structures and functions in living patients with high precision.

This funding opportunity supports researchers and teams developing advanced imaging technologies to visualize the inner ear's structures and functions in living humans, aiming for greater detail and accuracy in non-invasive clinical settings.

This funding opportunity supports early-stage postdoctoral researchers in transitioning to independent faculty positions by providing financial resources for conducting basic experimental studies involving human participants in cancer research.

This program provides funding to early-stage postdoctoral researchers in cancer-related fields to help them transition from mentored training to independent research careers.

This grant provides financial support to early-stage postdoctoral researchers in cancer-related fields, helping them transition from mentored training to independent research careers.

This funding opportunity provides financial support for research projects that aim to improve understanding and treatment of substance use disorders by exploring prevention strategies and engaging community stakeholders.

The purpose of this NOFO is to seek applications for a Coordinating Center (CC) for the Multi-Sectoral Preventive Interventions (MSPI) Research Network. Members of the Multi-Sectoral Preventive Interventions (MSPI) Research Network, including the CC and separately funded research projects, will work collaboratively with the NIH to test prospective multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities. The MSPI Research Network will include the CC funded under this Cooperative Agreement and up to 10 Research Projects funded under the companion UG3/UH3 Phased Cooperative Agreement NOFO, Multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities. The CC will provide overarching support and guidance to the network in three domains: (1) administration, coordination, and communication; (2) methodology, data, and analytic support and consultation; and (3) community and other collaborator engagement and dissemination support. It is important that applicants for the CC also read the companion NOFO to understand the full mission and structure of the research network.

This funding opportunity supports researchers conducting observational studies to improve understanding and treatment of musculoskeletal, rheumatic, and skin diseases, with a focus on patient outcomes and disease progression.

This grant provides funding for researchers to conduct early-stage clinical trials aimed at improving treatments for patients with arthritis, musculoskeletal, or skin diseases.

This funding opportunity supports innovative research projects that explore the effective use and sharing of genomic information in clinical care for diverse populations, regardless of their racial, ethnic, or socioeconomic backgrounds.

This funding opportunity provides financial support for researchers to explore innovative ways to integrate genomic information into clinical care, particularly focusing on diverse and underserved populations to improve health equity.

The purpose of this NOFO is to support projects to test prospective multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities. These research projects will be part of the Multi-Sectoral Preventive Interventions (MSPI) Research Network, which will also include a Coordinating Center (NOFO xxx). Funded under a cooperative agreement, projects participating in the MSPI Research Network will collaborate to share approaches, methods, and data, working closely with NIH Institutes, Offices and Centers. Applicants applying to this NOFO are encouraged to review the Coordinating Center NOFO to fully understand the MSPI Research Network structure and activities. This NOFO solicits bi-phasic research projects proposed in UG3/UH3 Phased Innovation Awards Cooperative Agreement applications. Funding for the UG3 phase (phase I) will be used to demonstrate sufficient preparation, feasibility and capacity to meet foundational milestone targets specific to the work proposed. A UG3 project that meets its milestones will be administratively considered by NIH and prioritized for transition to the UH3 award (phase II). Applicants responding to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases.

This funding opportunity supports innovative research projects that aim to improve the use of genomic information in clinical care, particularly for diverse and underrepresented populations, while addressing health disparities and enhancing the integration of genomic medicine into healthcare practices.

This Notice of Funding Opportunity Announcement (NOFO) intends to supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.

This grant provides funding to neuroscience researchers to advance their small molecule drug discovery and development projects aimed at treating disorders of the nervous system.

This funding opportunity supports researchers developing innovative technologies to enhance the delivery of treatments for HIV and substance use disorders, focusing on improving patient outcomes and understanding the effects of addictive substances.

The National Cancer Institute is offering funding for research projects aimed at validating the effectiveness of various markers and assays in cancer detection, diagnosis, treatment, and prevention, with a focus on developing these into clinical assays and ensuring their performance across multiple laboratories.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: (1) Courses for Skills Development; and (2) Develop and implement a program to prepare nurse scientists, and scientists in aligned fields, to conduct research on the social determinants of health in alignment with the NINR Strategic Plan.

This funding opportunity supports U.S.-based researchers and organizations in developing non-addictive pain relief therapies to combat the opioid crisis, with a focus on advancing preclinical candidates toward clinical trials.